Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Halozyme Therapeutic (HALO)

Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,360,790
  • Shares Outstanding, K 118,474
  • Annual Sales, $ 1,397 M
  • Annual Income, $ 316,890 K
  • EBIT $ 594 M
  • EBITDA $ 687 M
  • 60-Month Beta 0.98
  • Price/Sales 5.23
  • Price/Cash Flow 12.92
  • Price/Book 148.47

Options Overview Details

View History
  • Implied Volatility 34.78% (-5.53%)
  • Historical Volatility 36.62%
  • IV Percentile 24%
  • IV Rank 18.11%
  • IV High 59.09% on 04/04/25
  • IV Low 29.41% on 06/16/25
  • Expected Move (DTE 17) 2.93 (4.54%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 556
  • Volume Avg (30-Day) 385
  • Put/Call OI Ratio 0.44
  • Today's Open Interest 10,463
  • Open Int (30-Day) 13,017
  • Expected Range 61.68 to 67.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $1.55
  • Number of Estimates 4
  • High Estimate $1.70
  • Low Estimate $1.42
  • Prior Year $1.03
  • Growth Rate Est. (year over year) +50.49%

Price Performance

See More
Period Period Low Period High Performance
1-Month
61.33 +5.36%
on 03/27/26
71.53 -9.67%
on 03/04/26
-4.92 (-7.08%)
since 02/27/26
3-Month
61.33 +5.36%
on 03/27/26
82.22 -21.42%
on 02/09/26
-4.26 (-6.19%)
since 12/26/25
52-Week
47.50 +36.02%
on 05/14/25
82.22 -21.42%
on 02/09/26
+0.77 (+1.21%)
since 03/28/25

Most Recent Stories

More News
Unpacking Q4 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks

Unpacking Q4 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks

HALO : 64.61 (+3.99%)
Halozyme Appoints David Ramsay as Interim Chief Financial Officer

SAN DIEGO , March 12, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today announced that David Ramsay has been appointed Interim Chief Financial Officer...

HALO : 64.61 (+3.99%)
U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma

FDA approval based on Phase 3 data demonstrating statistically significant improvements in progression ‑free survival and overall survival versus standard of care regimens

HALO : 64.61 (+3.99%)
2 Reasons to Like HALO (and 1 Not So Much)

2 Reasons to Like HALO (and 1 Not So Much)

HALO : 64.61 (+3.99%)
Halozyme Therapeutics (NASDAQ:HALO) Surprises With Q4 CY2025 Sales

Halozyme Therapeutics (NASDAQ:HALO) Surprises With Q4 CY2025 Sales

HALO : 64.61 (+3.99%)
Halozyme Therapeutics: Q4 Earnings Snapshot

Halozyme Therapeutics: Q4 Earnings Snapshot

HALO : 64.61 (+3.99%)
HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE

Full Year 2025 Total Revenue Increased 38% YOY to Record $1.397 billion Full Year 2025 Royalty Revenue Increased 52% YOY to Record $868 million

HALO : 64.61 (+3.99%)
Acadia Healthcare, Hims & Hers Health, RadNet, Halozyme Therapeutics, and Privia Health Shares Are Soaring, What You Need To Know

Acadia Healthcare, Hims & Hers Health, RadNet, Halozyme Therapeutics, and Privia Health Shares Are Soaring, What You Need To Know

ACHC : 23.39 (+2.45%)
HIMS : 20.76 (+10.54%)
PRVA : 20.57 (+2.75%)
HALO : 64.61 (+3.99%)
RDNT : 55.89 (+0.27%)
Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results

SAN DIEGO , Feb. 10, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2025 financial and operating results...

HALO : 64.61 (+3.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Halozyme Therapeutics Inc. is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company's ENHANZE drug delivery technology helps in developing subcutaneous formulation of drugs. The company...

See More

Key Turning Points

3rd Resistance Point 63.10
2nd Resistance Point 62.66
1st Resistance Point 62.39
Last Price 64.61
1st Support Level 61.68
2nd Support Level 61.24
3rd Support Level 60.97

See More

52-Week High 82.22
Fibonacci 61.8% 68.96
Fibonacci 50% 64.86
Last Price 64.61
Fibonacci 38.2% 60.76
52-Week Low 47.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.